TRITON and Beyond: New Insights into the Profile of Prasugrel

Cardiovascular Therapeutics

Volumn 30, Issue 4, 2012, Pages

  Jakubowski, Joseph A ^a   Riesmeyer, Jeffrey S ^a   Close, Sandra L ^a   Leishman, Amy G ^a   Erlinge, David ^b  

^a ELI LILLY AND COMPANY   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Acute coronary syndrome; Clopidogrel; P2Y 12; Prasugrel; Thienopyridines

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; DIGOXIN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN P; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; PRASUGREL; PROTON PUMP INHIBITOR;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CORONARY STENT; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG INTERACTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; DRUG INTERACTIONS; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; THIOPHENES; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863441791     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00263.x     Document Type: Review

References (86)

1. 12 receptor antagonist activity. Semin Thromb Haemost 2005;31:184-194.
2. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173.
3. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545-1551.
4. 12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother 2008;9:2893-2900.
5. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basic for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25:357-374.
6. Wiviott SD, Braunwald E, McCabe CH, et al. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2007;357:2001-2015.
7. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis in Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51:2028-2033.
8. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: An application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-2764.
9. Murphy SA, Antman EM, Wiviott SD, et al. for the TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-2479.
10. Serruys PW, de Jaegere P, Kiemeneij F, et al. for The Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
11. Pfisterer M, Brunner-La Rocca HP, et al. BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591.
12. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
13. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
14. Wiviott SD, Braunwald E, McCabe CH, et al. for the TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: A subanalysis of a randomised trial. Lancet 2008;371:1353-1363.
15. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Eng J Med 1996;334:1084-1089.
16. Leon MB, Baim DS, Popma JJ, et al. for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Eng J Med 1998;339:1665-1671.
17. Mandelzweig L, Battler A, et al. on behalf of the Euro Heart Survey Investigators. The second Euro heart survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006;27:2285-2293.
18. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, for the TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009;373:723-731.
19. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Int Med 1975;82:733-738.
20. Colwell JA, Halushka PV, Sarji K, Levine J, Sagel J, Nair RM. Altered platelet function in diabetes mellitus. Diabetes 1976;25:826-831.
21. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-716.
22. Serebruany VL, Malinin AI, Pokov A, Barsness G, Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am Heart J 2008;155:93.e1-93.e7.
23. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372-374.
24. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA 2007;298:765-775.
25. Wiviott SD, Braunwald E, Angiolillo DJ, et al. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636.
26. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-2950.
27. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396.
28. Wolfram RM, Torguson RL, Hassani SE, et al. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol 2006;97:984-989.
29. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-1977
30. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011. doi:.
31. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526.
32. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.
33. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies: Clopidogrel does one size fit all?Circulation 2006;114:e600-e606.
34. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516.
35. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
36. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750.
37. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-1934.
38. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: One piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010;56:112-116.
39. Bonello L, Tantry US, Marcucci R, et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933.
40. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
41. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009;373:309-317.
42. Simon T, Verstuyft C, Mary-Krause M, et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
43. Mega JL, Simon T, Anderson JL, et al. CYP2C19 genetic variants and clinical outcomes with clopidogrel: A collaborative meta-analysis. Circulation 2009;120:S598-S599.
44. Giusti B, Gori AM, Marcucci R, Abbate R. Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opin Drug Metab Toxicol 2010;6:393-407.
45. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis. J Am Coll Cardiol 2010;56:134-143.
46. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009;30:1744-1752.
47. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-2560.
48. Ishikawa T, Sakurai A, Hirano H, Lezhava A, Sakurai M, Hayashizaki Y. Emerging new technologies in pharmacogenomics: Rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC transporter ABCB1 (P-gp/MDR1). Pharmacol Ther 2010;126:69-81.
49. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486-501.
50. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010;376:1312-1319.
51. Effient US package insert: Accessed September, 2010.
52. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89:65-74.
53. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
54. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors and clopidogrel. Throm Haemost 2009;101:714-719.
55. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet 2009;374:989-997.
56. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-741.
57. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007;49:167-173.
58. Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, Salazar DE. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010;49:777-798.
59. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-754.
60. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-539.
61. Lordkipanidze M, Diodati JG, Schampaert E, Palisaitis DA, Sia E, Pharand C. Effect of clopidogrel discontinuation on platelet function. Circulation 2009;120:S1032.
62. Ho PM, Tsai TT, Wang TY, et al. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes 2010;3:303-308.
63. Sibbing D, Stegherr J, Braun S, et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 2010;55:558-565.
64. Frelinger AL 3rd, Barnard MR, Fox ML, Michelson AD. The Platelet Activity after Clopidogrel Termination (PACT) Study. Circ Cardiovasc Intert 2010;3:442-449.
65. Angiolillo DJ, Jakubowski JA, Frelinger AL, et al. Lack of rebound platelet activation following washout periods following prasugrel or clopidogrel in diabetic patients with coronary artery disease. Eur Heart J 2010;31(Suppl):P2315(389).
66. Small DS, Wrishko RE, Ernest CS 2nd, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 2009;34:585-594.
67. Payne CD, Li YG, Brandt JT, et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 2008;19:275-281.
68. 12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008;99:409-415.
69. Angiolillo DJ, Saucedo J, DeRaad R, Frelinger A, Gurbel P, Costigan T, Jakubowski JA, Ojeh C, Effron MB. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: Results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010;56:1017-1023.
70. Wiviott SD, Trenk D, Frelinger AL, et al. PRINCIPLE-TIMI 44 investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007;116:2923-2932.
71. Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomized, double-blind ACAPULCO study. Thromb Haemost 2010;103:213-223.
72. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of competitive effect. Thromb Res 2008;121:527-534.
73. Wrishko RE, Ernest CS 2nd, Small DS, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 2009;49:984-998.
74. Riesmeyer J, Salazar DE, Weerakkody G, et al. Relationship between exposure to prasugrel active metabolite and clinical outcomes in TRITON-TIMI 38. Submitted to J Clin Pharmacol.
75. Chin CT, Roe MT, Fox KA, et al. TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16-22.
76. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122:394-403.
77. Small DS, Kothare P, Yuen E, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010;66:127-135.
78. Small DS, Payne CD, Kothare P, et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: An open-label trial. Clin Ther 2010;32:365-379.
79. Small DS, Li YG, Ernest CS 2nd, et al. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. J Clin Pharmacol 2010; 2010 Apr 21. [Epub ahead of print].
80. Kaul S, Diamond GA. Prasugrel and cancer: An uncertain association or a credible risk that meaningfully alters the benefit-risk balance. Arch Int Med 2010;170:1010-1012.
81. Floyd JS, Serebruany VL. Prasugrel as a potential cancer promoter: Review of the unpublished data. Arch Int Med 2010;170:1078-1080.
82. Serebruany V, Floyd J, Chew D. Excess of solid cancers after prasugrel: The food and drug administration outlook. Am J Ther 2010. doi:.
83. Ohman EM, Roe MT, Armstrong PW, Fox KA, Prabhakaran D, White HD. Public sensationalism and clinical trials: How to address the challenges of science?Am J Med 2010;123:481-483.
84. Unger EF. Weighing benefits and risks-The FDA's review of prasugrel. N Engl J Med 2009;361:942-945.
85. US Food and Drug Administration. Drug approval package: Effient (prasugrel) tablets. Available at: Accessed September, 2010.
86. Jakubowski JA. Beyond platelet functional testing: Value in the aggregate. Biomarkers Med 2011. doi:.